Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Editas Medicine, Inc. - Common Stock
(NQ:
EDIT
)
3.340
-0.120 (-3.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Editas Medicine, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Preview: Editas Medicine's Earnings
↗
May 04, 2023
Via
Benzinga
Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data
May 01, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events
May 01, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
The 3 Most Promising Gene Editing Stocks to Buy in 2023
↗
April 28, 2023
Intellia, Beam, and Editas are using gene editing to cure incurable diseases. These are three gene editing stocks you'll want to invest in.
Via
InvestorPlace
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
April 27, 2023
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end
From
Editas Medicine, Inc.
Via
GlobeNewswire
2 Stocks Under $15 Per Share to Consider
↗
April 16, 2023
Anyone can get in on the stock market at these prices.
Via
The Motley Fool
Why Shares of Editas Medicine Rose Monday
↗
April 17, 2023
The company is benefiting from positive news affecting other gene-editing stocks.
Via
The Motley Fool
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?
↗
April 13, 2023
While CRSPR stock captured the spotlight for potentially encouraging drug data, the news lifted other gene-editing stocks.
Via
InvestorPlace
Editas Medicine Earnings Preview
↗
February 21, 2023
Via
Benzinga
Top CRISPR Stocks
↗
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
April 13, 2023
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.
Via
Benzinga
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
↗
April 13, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director
April 13, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Proceed With Caution When Considering These 5 Ultra-Popular Stocks
↗
April 13, 2023
Four of these five stocks are losing money.
Via
The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
↗
April 06, 2023
Neither stock is a good choice for those who can't handle a lot of risk.
Via
The Motley Fool
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future?
↗
April 03, 2023
EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future.
Via
The Motley Fool
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It
↗
March 30, 2023
Editas Medicine is a high-risk stock with the potential of a big reward.
Via
The Motley Fool
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
↗
March 29, 2023
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.
Via
InvestorPlace
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
↗
March 25, 2023
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.
Via
InvestorPlace
Thinking of Buying Biotech Stocks? Do These 3 Things First
↗
March 22, 2023
It's better to plan ahead than to get caught by surprise.
Via
The Motley Fool
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
March 08, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
February 22, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
These 2 Biotech Stocks Could Soar in the Next Bull Market
↗
February 17, 2023
They're both at the cutting edge of gene-editing technology.
Via
The Motley Fool
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
↗
February 16, 2023
Which of these rebounding biotech stocks is the better buy right now?
Via
The Motley Fool
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
February 15, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
3 No-Brainer Stocks to Buy Right Now for Less Than $25
↗
February 04, 2023
All three healthcare stocks are showing solid long-term potential.
Via
The Motley Fool
Why Editas Medicine's Shares Jumped This Week
↗
February 03, 2023
The gene-editing biotech's shares have had a strong two-week run.
Via
The Motley Fool
Is Editas Medicine Stock a Buy Now?
↗
February 03, 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
Via
The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
↗
February 02, 2023
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.
Via
InvestorPlace
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
